BACKGROUND At the end of 2 previous trials, an excess of stroke and bleeding was observed in patients with AF
A trial fibrillation (AF) predisposes patients to an increased risk of embolic stroke and is associated with a higher mortality rate than sinus rhythm (1) (2) (3) . Warfarin and other vitamin K antagonists (VKAs) are highly effective in preventing stroke, but limited by their narrow therapeutic window and inconveniences imposed by the need for coagulation monitoring and frequent dose adjustments (4-6).
Four new oral anticoagulants (NOACs) that inhibit thrombin or activated factor X (factor Xa) in a dosedependent fashion and do not require regular monitoring have been found to be at least as effective and safe as warfarin for preventing stroke and systemic embolic events (SEE) in patients with AF in their respective phase 3 trials (7) (8) (9) (10) . In the 2 previous trials investigating factor Xa inhibitors, the ROCKET AF Table 2 ). INR measurements were mandated at days 4 to 6, 7 to 10, and 11 to 14 and as often as needed through day 30 until the patient was confirmed to be in therapeutic range. Open-label INR testing was not allowed on days 1 to 3 to avoid unblinding so as to maintain the integrity of the trial. STATISTICAL ANALYSIS. Evaluation of the efficacy and safety at the end-of-study transition plan in the ENGAGE AF-TIMI 48 trial was pre-specified.
Descriptive statistics of baseline characteristics were Values are median (interquartile range) or n (%). *Patients with a creatinine clearance #50 ml/min or body weight 60 kg or less, as well as patients who were receiving the concomitant strong P-glycoprotein inhibitors verapamil or quinidine at randomization, received a 50% reduction in the dose of edoxaban to maintain similar exposure to the patients who did not have any of these 3 factors. Some patients had more than 1 reason for dose adjustment.
AF ¼ atrial fibrillation; CHADS2 ¼ stroke risk factor scoring system where 1 point is given for history of congestive heart failure (C), hypertension (H), age $75 years (A), diabetes (D), and 2 points given for history of stroke or transient ischemic attack (S); TIA ¼ transient ischemic attack; VKA ¼ vitamin K antagonist. Outcomes included all-cause stroke or SEE, ischemic stroke, hemorrhagic stroke, all-cause mortality, major bleeding (defined by the International Society on Thrombosis and Haemostasis) (18) , and intracranial hemorrhage. Hazard ratios for edoxaban and warfarin with 95% confidence intervals were determined using Cox proportional hazards models with treatment as the only covariate. Cumulative incidence curves for the attainment of a therapeutic INR $2.0 were constructed using the Kaplan-Meier approach and compared using the log-rank test. All analyses were performed with Stata version 12.1 (Stata Corp., College Station, Texas). 
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FIGURE 2 Stroke or SEE
Occurrence of stroke or systemic embolic during the 30-day transition period at the end of the trial. HD ¼ high dose; Hem ¼ hemorrhagic; HR ¼ hazard ratio; Isch ¼ ischemic; 
FIGURE 3 Bleeding Events
Occurrence of major bleeding during the 30-day transition period at the end of the trial. Figure 2 .
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A U G U S T 1 2 , 2 0 1 4 : 5 7 6 -8 4 treatment arms: warfarin 7 events (1.90%/year), edoxaban high dose 7 events (1.89%/year), and edoxaban low dose 7 events (1.85%/year) ( Table 2) .
Six of the 7 strokes in each group were ischemic.
Major bleeding was also similar across the 3 randomized treatment arms during the 30-day end-of-study transition period (Fig. 3) : warfarin 11 events (2.98%/ year), edoxaban high dose 10 events (2.69%/year), and edoxaban low dose 18 events (4.76%/year) ( Table 2 ).
Major bleeding was also similar from days 1 to 14 when a transition kit and open-label VKA were given together (warfarin 6 events, edoxaban high dose 4 events, edoxaban low dose 5 events) (Fig. 3) . During the 30-day period after the end of the study, there were 25 deaths balanced across the 3 treatment arms: warfarin 7 (1.89%/year), edoxaban high dose 8 (2.15%/year), edoxaban low dose 10 (2.64%/year) ( Table 2) .
TRANSITION OF PATIENTS TO OPEN-LABEL VKA.
The results were consistent regardless of the openlabel anticoagulant selected for transition ( Table 2) . 
TRANSITION OF PATIENTS TO OPEN-LABEL NOAC.
In the 4,258 (31.2%) patients transitioned to NOACs, there were no significant differences in the rates of stroke for patients in the 3 groups: warfarin 2 events (1.84%/year), edoxaban high-dose 2 events (1.69%/ year), edoxaban low-dose 3 events (2.46%/year) ( Table 2) . There were similar rates of major bleeding Figure 2 . Ruff et al.
A U G U S T 1 2 , 2 0 1 4 : 5 7 6 -8 4
Transition Plan at End of Anticoagulation Trial
